Six months after raising $69 million to support the anticipated launch of hepatitis B vaccine Heplisav, Dynavax Technologies Corp. is at it again. The Berkeley, Calif.-based biotech completed another public offering, this time raising $74.4 million for more Heplisav ramp-up.